{"id":"potassium","rwe":[{"pmid":"41913095","year":"2026","title":"Beyond silver: innovative use of gold nanoparticles for anthracnose management and plant immunity enhancement in chilli.","finding":"","journal":"Pest management science","studyType":"Clinical Study"},{"pmid":"41912740","year":"2026","title":"A potassium titanate whisker-assisted method for genetic transformation of Phanerochaete chrysosporium using a Cas9-sGFP expression vector.","finding":"","journal":"World journal of microbiology & biotechnology","studyType":"Clinical Study"},{"pmid":"41911485","year":"2026","title":"The use of potassium-competitive acid blockers in the management of foregut disease.","finding":"","journal":"Current opinion in gastroenterology","studyType":"Clinical Study"},{"pmid":"41910839","year":"2026","title":"MitoQ Triggers Mitochondrial Collapse and Apoptotic Death in Glioblastoma Associated with KATP Channel Expression Changes.","finding":"","journal":"Neurochemical research","studyType":"Clinical Study"},{"pmid":"41910484","year":"2026","title":"Fractional Excretion of Potassium Predicts Remission in Adult Nephrotic Syndrome.","finding":"","journal":"Kidney360","studyType":"Clinical Study"}],"_fda":{"id":"3f74c669-3182-952f-e063-6294a90aad92","set_id":"00615fad-ad3b-46e8-a89d-48290d937ae2","openfda":{"upc":["0342806422106","0342806423103"],"unii":["660YQ98I10"],"route":["ORAL"],"rxcui":["312529","628953"],"spl_id":["3f74c669-3182-952f-e063-6294a90aad92"],"brand_name":["Potassium Chloride"],"spl_set_id":["00615fad-ad3b-46e8-a89d-48290d937ae2"],"package_ndc":["42806-423-01","42806-423-05","42806-423-10","42806-422-01","42806-422-05","42806-422-10"],"product_ndc":["42806-422","42806-423"],"generic_name":["POTASSIUM CHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["POTASSIUM CHLORIDE"],"manufacturer_name":["Epic Pharma, LLC"],"application_number":["ANDA209314"],"is_original_packager":[true]},"version":"6","pregnancy":["8.1 Pregnancy Risk Summary There are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted. Potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. The background risk for major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively."],"overdosage":["10 OVERDOSAGE 10.1 Symptoms The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, potentially fatal hyperkalemia can result [see Contraindications and Warnings] . It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5 to 8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L). 10.2 Treatment Treatment measures for hyperkalemia include the following: 1. Elimination of foods and medications containing potassium and of any agents with potassium-sparing properties. 2. Intravenous administration of 300 to 500 mL/hr of 10% dextrose solution containing 10 to 20 units of crystalline insulin per 1,000 mL. 3. Correction of acidosis, if present, with intravenous sodium bicarbonate. 4. Use of exchange resins, hemodialysis or peritoneal dialysis. In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce digitalis toxicity. The extended release feature means that absorption and toxic effects may be delayed for hours. Consider standard measures to remove any unabsorbed drug."],"description":["11 DESCRIPTION Potassium Chloride Extended-Release Tablets, USP are a solid oral dosage form of potassium chloride. Each contains 600 mg or 750 mg of potassium chloride equivalent to 8 mEq or 10 mEq of potassium in a wax matrix tablet. Potassium Chloride Extended-Release Tablets, USP are an electrolyte replenisher. The chemical name is potassium chloride, and the structural formula is KCl. Potassium chloride, USP is a white, granular powder or colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol. Inactive Ingredients: colloidal silicon dioxide, hydroxypropyl cellulose and hydrogenated vegetable oil. The film coating contains lecithin, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide. FDA approved dissolution test specifications differ from USP."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Potassium Chloride Extended-Release Tablets, USP contain 600 mg or 750 mg of Potassium Chloride, USP (equivalent to 8 mEq and 10 mEq respectively), and are provided as extended release tablets. Table 1: How Supplied Dose Shape Color Debossment Bottle of 100 tablets Bottle of 500 tablets Bottle of 1000 tablets 600 mg (8 mEq) Round White to off-white “YH” and “106” on one side, and “8” on the other side 42806-422-01 42806-422-05 42806-422-10 750 mg (10 mEq) Round White to off-white “YH” and “105” on one side, and “10” on the other side 42806-423-01 42806-423-05 42806-423-10 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature.] Protect from light and moisture. Dispense in a tight container as defined in the USP with a child-resistant closure."],"geriatric_use":["8.5 Geriatric Use Clinical studies of potassium chloride extended-release tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in the pediatric population have not been established."],"effective_time":"20250923","nursing_mothers":["8.2 Lactation Risk Summary The normal potassium ion content of human milk is about 13 mEq per liter. Since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk."],"pharmacokinetics":["12.3 Pharmacokinetics The potassium chloride in potassium chloride extended-release tablets is completely absorbed before it leaves the small intestine. The wax matrix is not absorbed and is excreted in the feces; in some instances the empty matrices may be noticeable in the stool. When the bioavailability of the potassium ion from the potassium chloride extended-release tablets is compared to that of a true solution the extent of absorption is similar. The extended-release properties of potassium chloride extended-release tablets are demonstrated by the finding that a significant increase in time is required for renal excretion of the first 50% of the potassium chloride extended-release tablets dose as compared to the solution. Increased urinary potassium excretion is first observed 1 hour after administration of potassium chloride extended-release tablets, reaches a peak at approximately 4 hours, and extends up to 8 hours. Mean daily steady-state plasma levels of potassium following daily administration of potassium chloride extended-release tablets cannot be distinguished from those following administration of potassium chloride solution or from control plasma levels of potassium ion. Specific Populations Cirrhotics Based on publish literature, the baseline corrected serum concentrations of potassium measured over 3 hours after administration in cirrhotic subjects who received an oral potassium load rose to approximately twice that of normal subjects who received the same load."],"adverse_reactions":["6 ADVERSE REACTIONS The most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort and diarrhea. (6) To report SUSPECTED ADVERSE REACTIONS, contact Epic Pharma, LLC at 1-888-374-2791 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch The following adverse reactions have been identified with use of oral potassium salts. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. There have been reports hyperkalemia and of upper and lower gastrointestinal condition including obstruction, bleeding, ulceration, perforation. Skin rash has been reported rarely."],"contraindications":["4 CONTRAINDICATIONS Potassium chloride is contraindicated in patients on triamterene and amiloride. Concomitant use with triamterene and amiloride (4)"],"drug_interactions":["7 DRUG INTERACTIONS Triamterene and amiloride: Concomitant use is contraindicated (7.1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia (7.2) Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia (7.3) 7.1 Triamterene or amiloride Use with triamterene or amiloride can produce severe hyperkalemia. Concomitant use is contraindicated [see Contraindications (4) ]. 7.2 Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients on concomitant RAAS inhibitors. 7.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) NSAIDS may produce potassium retention by reducing renal synthesis of prostaglandin E and imparing the renin-angiotensin system. Closely monitor potassium in patients on concomitant NSAIDs."],"how_supplied_table":["
Table 1: How Supplied
DoseShapeColorDebossmentBottle of 100 tabletsBottle of 500 tabletsBottle of 1000 tablets
600 mg (8 mEq) Round White to off-white “YH” and “106” on one side, and “8” on the other side42806-422-0142806-422-0542806-422-10
750 mg (10 mEq) Round White to off-white “YH” and “105” on one side, and “10” on the other side 42806-423-0142806-423-0542806-423-10
"],"mechanism_of_action":["12.1 Mechanism of Action The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day. 12.3 Pharmacokinetics The potassium chloride in potassium chloride extended-release tablets is completely absorbed before it leaves the small intestine. The wax matrix is not absorbed and is excreted in the feces; in some instances the empty matrices may be noticeable in the stool. When the bioavailability of the potassium ion from the potassium chloride extended-release tablets is compared to that of a true solution the extent of absorption is similar. The extended-release properties of potassium chloride extended-release tablets are demonstrated by the finding that a significant increase in time is required for renal excretion of the first 50% of the potassium chloride extended-release tablets dose as compared to the solution. Increased urinary potassium excretion is first observed 1 hour after administration of potassium chloride extended-release tablets, reaches a peak at approximately 4 hours, and extends up to 8 hours. Mean daily steady-state plasma levels of potassium following daily administration of potassium chloride extended-release tablets cannot be distinguished from those following administration of potassium chloride solution or from control plasma levels of potassium ion. Specific Populations Cirrhotics Based on publish literature, the baseline corrected serum concentrations of potassium measured over 3 hours after administration in cirrhotic subjects who received an oral potassium load rose to approximately twice that of normal subjects who received the same load."],"indications_and_usage":["1 INDICATIONS AND USAGE Potassium Chloride Extended-Release Tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. Potassium Chloride Extended-Release Tablets are a potassium salt, indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. (1)"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Gastrointestinal Irritation: Take with meals (5.1) 5.1 Gastrointestinal Adverse Reactions Solid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract, particularly if the drug maintains contact with the gastrointestinal mucosa for prolonged periods. Consider the use of liquid potassium in patients with dysphagia, swallowing disorders, or severe gastrointestinal motility disorders. If severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occurs, discontinue potassium chloride extended-release tablets and consider possibility of ulceration, obstruction or perforation. Potassium chloride extended-release tablets should not be taken on an empty stomach because of its potential for gastric irritation [see Dosage and Administration (2.1) ] ."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility Carcinogenicity, mutagenicity and fertility studies in animals have not been performed. Potassium is a normal dietary constituent."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Inform patients to take each dose with meals and with a full glass of water or other liquid, and to not crush, chew, or suck the tablets. Inform patients that the wax matrix is not absorbed and is excreted in the feces; in some instances the empty matrices may be noticeable in the stool. Advise patients seek medical attention if tarry stools or other evidence of gastrointestinal bleeding is noticed. Distributed by: Epic Pharma, LLC Laurelton, NY 11413 Product of Israel. Revised 06/2025 ZLN036"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Monitor serum potassium and adjust dosages accordingly (2.1) If serum potassium is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation (2.1) Take with meals and with a glass of water or other liquid. Swallow tablets whole without crushing, chewing or sucking. (2.1) Treatment of hypokalemia : Doses range from 40 to 100 mEq/day in divided doses. Limit doses to 40 mEq per dose. (2.2) Prevention of hypokalemia : Typical dose is 20 mEq per day. (2.2) 2.1 Administration and Monitoring If serum potassium concentration is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation. Monitoring Monitor serum potassium and adjust dosages accordingly. Monitor serum potassium periodically during maintenance therapy to ensure potassium remains in desired range. The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis, requires careful attention to acid-base balance, volume status, electrolytes, including magnesium, sodium, chloride, phosphate, and calcium, electrocardiograms, and the clinical status of the patient. Correct volume status, acid-base balance, and electrolyte deficits as appropriate. Administration Take potassium chloride extended-release tablets with meals and with a glass of water or other liquid. Do not take potassium chloride extended-release tablets on an empty stomach because of its potential for gastric irritation [see Warnings and Precautions ( 5.1 )] . Swallow tablets whole without crushing, chewing or sucking. 2.2 Dosing Dosage must be adjusted to the individual needs of each patient. Dosages greater than 40 mEq per day should be divided such that no more than 40 mEq is given in a single dose. Treatment of Hypokalemia: Typical dose range is 40 to 100 mEq per day. Maintenance or Prophylaxis: Typical dose range is 20 mEq per day."],"spl_product_data_elements":["Potassium Chloride Potassium Chloride HYDROGENATED COTTONSEED OIL HYDROXYPROPYL CELLULOSE, UNSPECIFIED SILICON DIOXIDE POLYVINYL ALCOHOL TITANIUM DIOXIDE POLYETHYLENE GLYCOL, UNSPECIFIED LECITHIN, SOYBEAN TALC POTASSIUM CHLORIDE POTASSIUM CATION white to off-white Biconvex YH;105;10 Potassium Chloride Potassium Chloride LECITHIN, SOYBEAN TALC HYDROGENATED COTTONSEED OIL HYDROXYPROPYL CELLULOSE, UNSPECIFIED SILICON DIOXIDE POLYVINYL ALCOHOL TITANIUM DIOXIDE POLYETHYLENE GLYCOL, UNSPECIFIED POTASSIUM CHLORIDE POTASSIUM CATION white to off-white Biconvex YH;106;8"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Potassium Chloride Extended-Release Tablets, USP are supplied as: The 8 mEq (600 mg) tablets are white to off-white, round, biconvex, coated tablets, debossed with “YH” and “106” on one side, and “8” on the other side. The 10 mEq (750 mg) tablets are white to off-white, round, biconvex, coated tablets, debossed with “YH” and “105” on one side, and “10” on the other side. Tablets: 600 mg (8 mEq) and 750 mg (10 mEq) (3)"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Cirrhosis: Initiate therapy at the low end of the dosing range (8.6) Renal Impairment: Initiate therapy at the low end of the dosing range (8.7) 8.1 Pregnancy Risk Summary There are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted. Potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. The background risk for major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. 8.2 Lactation Risk Summary The normal potassium ion content of human milk is about 13 mEq per liter. Since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk. 8.4 Pediatric Use Safety and effectiveness in the pediatric population have not been established. 8.5 Geriatric Use Clinical studies of potassium chloride extended-release tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. 8.6 Cirrhotics Based on publish literature, the baseline corrected serum concentrations of potassium measured over 3 hours after administration in cirrhotic subjects who received an oral potassium load rose to approximately twice that of normal subjects who received the same load. Patients with cirrhosis should usually be started at the low end of the dosing range, and the serum potassium level should be monitored frequently [ see Clinical Pharmacology (12.3) ] . 8.7 Renal Impairment Patients with renal impairment have reduced urinary excretion of potassium and are at substantially increased risk of hyperkalemia. Patients with impaired renal function, particularly if the patient is on RAAS inhibitors or NSAIDs, should usually be started at the low end of the dosing range because of the potential for development of hyperkalemia [see Drug Interactions ( 7.2 , 7.3 )] . The serum potassium level should be monitored frequently. Renal function should be assessed periodically."],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 42806-422-01 Potassium Chloride Extended-release Tablets, USP 8 mEq (600 mg) 100 Tablets Rx only NDC 42806-422-05 Potassium Chloride Extended-release Tablets, USP 8 mEq (600 mg) 500 Tablets Rx only NDC 42806-422-10 Potassium Chloride Extended-release Tablets, USP 8 mEq (600 mg) 1000 Tablets Rx only NDC 42806-423-01 Potassium Chloride Extended-release Tablets, USP 10 mEq (750 mg 100 Tablets Rx only NDC 42806-423-05 Potassium Chloride Extended-release Tablets, USP 10 mEq (750 mg) 500 Tablets Rx only NDC 42806-423-10 Potassium Chloride Extended-release Tablets, USP 10 mEq (750 mg) 1000 Tablets Rx only 600mg-100ct-epic 600mg-500ct-epic 600mg-1000ct-epic 750mg-100ct-epic.jpg 750mg-500ct-epic.jpg 750mg-1000ct-epic"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility Carcinogenicity, mutagenicity and fertility studies in animals have not been performed. Potassium is a normal dietary constituent."]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Oral","category":"route"},{"label":"For Solution","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Active","category":"status"},{"label":"treatment and prophylaxis of hypokalemia with or without metabolic alkalosis","category":"indication"},{"label":"treatment and prophylaxis of hypokalemia with or without metabolic alkalosis","category":"indication"},{"label":"Nesher Pharms","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"19344 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"18483 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"17441 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"15884 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"14791 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"14371 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"13295 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"12500 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"12481 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"11055 reports"}],"drugInteractions":[{"url":"/drug/triamterene-or-amiloride","drug":"Triamterene or Amiloride","action":"Contraindicated","effect":"severe hyperkalemia","source":"OpenFDA Label","drugSlug":"triamterene-or-amiloride"},{"url":"/drug/renin-angiotensin-aldosterone-inhibitors","drug":"Renin-angiotensin-aldosterone inhibitors","action":"Monitor","effect":"hyperkalemia","source":"OpenFDA Label","drugSlug":"renin-angiotensin-aldosterone-inhibitors"},{"url":"/drug/nonsteroidal-anti-inflammatory-drugs","drug":"Nonsteroidal anti-inflammatory drugs","action":"Monitor","effect":"hyperkalemia","source":"OpenFDA Label","drugSlug":"nonsteroidal-anti-inflammatory-drugs"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"reported","severity":"unknown"},{"effect":"Vomiting","drugRate":"reported","severity":"unknown"},{"effect":"Flatulence","drugRate":"reported","severity":"unknown"},{"effect":"Abdominal pain/discomfort","drugRate":"reported","severity":"unknown"},{"effect":"Diarrhea","drugRate":"reported","severity":"unknown"},{"effect":"Hyperkalemia","drugRate":"reported","severity":"unknown"},{"effect":"Upper gastrointestinal condition","drugRate":"reported","severity":"unknown"},{"effect":"Lower gastrointestinal condition","drugRate":"reported","severity":"unknown"},{"effect":"Obstruction","drugRate":"reported","severity":"unknown"},{"effect":"Bleeding","drugRate":"reported","severity":"unknown"},{"effect":"Ulceration","drugRate":"reported","severity":"unknown"},{"effect":"Perforation","drugRate":"reported","severity":"unknown"},{"effect":"Skin rash","drugRate":"reported","severity":"unknown"}],"contraindications":["Potassium chloride is contraindicated in patients on triamterene and amiloride.","Concomitant use with triamterene and amiloride is contraindicated."],"specialPopulations":{"Pregnancy":"There are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted. Potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. The background risk for major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.","Geriatric use":"Clinical studies of potassium chloride extended-release tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased renal function and concomitant use of other drugs in this population.","Paediatric use":"Safety and effectiveness in the pediatric population have not been established.","Renal impairment":"Initiate therapy at the low end of the dosing range"}},"trials":[],"aliases":[],"company":"Nesher Pharms","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=POTASSIUM","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:44:04.314495+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:44:11.484384+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:44:02.957894+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=POTASSIUM","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:44:12.290434+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:44:01.685335+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:44:01.685393+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:44:14.406767+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1141/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:44:13.304129+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:44:24.909096+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA209314","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:44:01.685403+00:00"}},"allNames":"potassium chloride","offLabel":[],"synonyms":["Potassium Chloride","POTASSIUM CHLORIDE"],"timeline":[{"date":"1986-04-16","type":"positive","source":"FDA Orange Book","milestone":"Ten-K approved — 10MEQ"},{"date":"1986-06-13","type":"positive","source":"FDA Orange Book","milestone":"Potassium Chloride approved — 10MEQ **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"1988-08-26","type":"positive","source":"FDA Orange Book","milestone":"Micro-K Ls approved — 20MEQ/PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"1990-12-17","type":"positive","source":"FDA Orange Book","milestone":"Potassium Chloride 10Meq In Plastic Container approved — 746MG/100ML"},{"date":"1998-08-11","type":"positive","source":"FDA Orange Book","milestone":"Potassium Chloride 20Meq In Plastic Container approved — 29.8MG/ML"},{"date":"2014-12-22","type":"positive","source":"FDA Orange Book","milestone":"Potassium Chloride approved — 20MEQ/15ML"},{"date":"2015-08-19","type":"positive","source":"FDA Orange Book","milestone":"Potassium Chloride approved — 20MEQ"},{"date":"2025-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from Torrent to Nesher Pharms"},{"date":"20250122","type":"positive","source":"OpenFDA","milestone":"FDA approval (Torrent)"}],"aiSummary":"Potassium Chloride is a small molecule medication originally developed by Torrent and currently owned by Nesher Pharms. It is used to treat and prevent hypokalemia (low potassium levels) with or without metabolic alkalosis. The medication is off-patent, with 56 generic manufacturers available. It was FDA-approved in 2025. Key safety considerations include careful monitoring of potassium levels to avoid hyperkalemia.","approvals":[{"date":"20250122","orphan":false,"company":"TORRENT","regulator":"FDA"}],"brandName":"Potassium Chloride","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day.","oneSentence":"Potassium Chloride works by replenishing potassium levels in the body.","technicalDetail":"Potassium Chloride acts as a potassium supplement, increasing serum potassium concentrations to treat and prevent hypokalemia. It is absorbed in the gastrointestinal tract and distributed throughout the body, where it helps to regulate various cellular functions."},"commercial":{"launchDate":"2025","_launchSource":"OpenFDA (20250122, TORRENT)"},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"POTASSIUM\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:\"POTASSIUM\"","fields":["approvals","company"],"source":"OpenFDA Drugs@FDA"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=potassium","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=potassium","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-31T10:38:27.711164","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:44:26.735870+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"potassium","indications":{"approved":[{"name":"treatment and prophylaxis of hypokalemia with or without metabolic alkalosis","source":"OpenFDA Label","regulator":"FDA"},{"name":"treatment and prophylaxis of hypokalemia with or without metabolic alkalosis","source":"OpenFDA Label","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Nesher Pharms","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT07502027","phase":"PHASE4","title":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2026-06-01","conditions":["Gastric Cancer (Diagnosis)","Gastric Cancer (GC)","Gastroesophageal Junction Adenocarcinoma"],"enrollment":55,"completionDate":"2029-06-30"},{"nctId":"NCT05441982","phase":"NA","title":"Saccharin and Acesulfame Potassium Consumption and Glucose Homeostasis in Older Adults With Prediabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2023-09-21","conditions":["Continuous Glucose Monitoring","Oral Glucose Tolerance","Insulin Sensitivity","Inflammatory Markers"],"enrollment":30,"completionDate":"2026-11-28"},{"nctId":"NCT07497893","phase":"NA","title":"FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)","status":"NOT_YET_RECRUITING","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2026-12-01","conditions":["Atrial Fibrillation (AF)","Upper Gastrointestinal Bleeding (UGIB)","Gastrointestinal Hemorrhage (Clinically Important, Upper)","Drug-Related Side Effects and Adverse Reactions"],"enrollment":1000,"completionDate":"2032-11-30"},{"nctId":"NCT00931463","phase":"PHASE4","title":"A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2009-09","conditions":["HIV Infections"],"enrollment":558,"completionDate":"2013-08"},{"nctId":"NCT01915212","phase":"PHASE1","title":"Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-09-26","conditions":["Healthy Volunteers"],"enrollment":69,"completionDate":"2017-03-06"},{"nctId":"NCT07494266","phase":"NA","title":"Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited Potassium Content in Patients With Chronic Kidney Disease: A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Karolinska Institutet","startDate":"2026-04-10","conditions":["Hyperkalemia","Chronic Kidney Disease (Stages 4 and 5)"],"enrollment":30,"completionDate":"2030-06-30"},{"nctId":"NCT06561711","phase":"PHASE4","title":"Optimization of Minocycline for Helicobacter Pylori Rescue Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-21","conditions":["Helicobacter Pylori Infection"],"enrollment":480,"completionDate":"2026-02-21"},{"nctId":"NCT07492134","phase":"PHASE2","title":"APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-04-01","conditions":["Acute Uncomplicated Diverticulitis"],"enrollment":100,"completionDate":"2028-10-01"},{"nctId":"NCT06977841","phase":"NA","title":"Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Zhongshan Hospital (Xiamen), Fudan University","startDate":"2025-06-10","conditions":["Helicobacter Pylori Eradication","Adverse Reaction"],"enrollment":640,"completionDate":"2026-03-10"},{"nctId":"NCT07171203","phase":"PHASE1","title":"Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-06","conditions":["Gastrointestinal Stromal Tumors"],"enrollment":18,"completionDate":"2031-07"},{"nctId":"NCT07493798","phase":"","title":"Serum Potassium Prediction Using Machine Learning and Single-lead ECG","status":"WITHDRAWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-20","conditions":["Infection","Heart Failure","Chronic Obstructive Pulmonary Disease","Asthma","Gout Flare","Chronic Kidney Diseases","Hypertensive Urgency","Atrial Fibrillation Rapid","Anticoagulants; Increased"],"enrollment":0,"completionDate":"2021-12-01"},{"nctId":"NCT05568498","phase":"PHASE2","title":"Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2025-01-20","conditions":["Parkinson Disease","Depression","PARKINSON DISEASE (Disorder)"],"enrollment":60,"completionDate":"2026-12-30"},{"nctId":"NCT05761080","phase":"PHASE4","title":"Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics","status":"RECRUITING","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2021-04-22","conditions":["Laparoscopic Appendectomy","Complicated Appendicitis","Periappendicular Abscess"],"enrollment":772,"completionDate":"2027-12"},{"nctId":"NCT07054905","phase":"","title":"Prediction of Hyperkalemia in Dialysis Patients Through Waveform Analysis Using Wearable ECG","status":"COMPLETED","sponsor":"Kyungho Park","startDate":"2025-06-23","conditions":["Hyperkalemia","Chronic Kidney Disease"],"enrollment":32,"completionDate":"2025-08-28"},{"nctId":"NCT04896281","phase":"NA","title":"Phenylalanine-free Diet for Patients With Secondary Hyperphenylalaninemia in ICU","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-07-30","conditions":["Non-Phenylketonuric Hyperphenylalaninemia"],"enrollment":100,"completionDate":"2026-12-31"},{"nctId":"NCT06287372","phase":"","title":"Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegia","status":"COMPLETED","sponsor":"Damascus University","startDate":"2022-07-04","conditions":["Myocardial Injury","Cardiac Surgery","Myocardial Protection"],"enrollment":20,"completionDate":"2023-07-04"},{"nctId":"NCT07483736","phase":"PHASE3","title":"Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients.","status":"NOT_YET_RECRUITING","sponsor":"Versailles Hospital","startDate":"2026-03","conditions":["C15.378"],"enrollment":1526,"completionDate":"2028-09"},{"nctId":"NCT06678685","phase":"PHASE2,PHASE3","title":"Spironolactone Improved Children With Gene Mutations Related to NCOR","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-10-30","conditions":["NCOR Gene Mutations","Spironolactone","ASD"],"enrollment":2,"completionDate":"2025-10-30"},{"nctId":"NCT06956599","phase":"PHASE3","title":"Hypersensitivity Reduction Efficacy: 5% Potassium Nitrate Toothpaste Compared to Colgate Cavity Protection Toothpaste","status":"COMPLETED","sponsor":"Colgate Palmolive","startDate":"2025-05-10","conditions":["Dentin Hypersensitivity"],"enrollment":80,"completionDate":"2025-08-11"},{"nctId":"NCT07482215","phase":"","title":"Prevalence and Molecular Identification of Human Schistosomiasis","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-05","conditions":["Schistosomiasis"],"enrollment":359,"completionDate":"2027-12"},{"nctId":"NCT07479615","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Mabgeek Biotech.Co.Ltd","startDate":"2026-05-01","conditions":["Atopic Dermatitis","Atopic Eczema"],"enrollment":498,"completionDate":"2029-01"},{"nctId":"NCT06244290","phase":"PHASE3","title":"Dentinal Hypersensitivity Reduction","status":"COMPLETED","sponsor":"Colgate Palmolive","startDate":"2020-09-28","conditions":["Dentinal Hypersensitivity"],"enrollment":123,"completionDate":"2020-10-21"},{"nctId":"NCT07469722","phase":"PHASE2,PHASE3","title":"POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2026-03-23","conditions":["Acute Heart Failure (AHF)","Congestive Heart Failure Acute","Diuretic Effect","Lung Ultrasonography Score","Ultrasonography, Doppler","Point-of-care Ultrasound (POCUS)"],"enrollment":128,"completionDate":"2028-07-01"},{"nctId":"NCT07478640","phase":"PHASE3","title":"Bioadhesive Film of Acmella Oleracea (Jambu) in the Reduction of Post-bleaching Dental Sensitivity Caused by Bleaching With 35% Hydrogen Peroxide.","status":"COMPLETED","sponsor":"Universidade Federal do Para","startDate":"2024-04-01","conditions":["Tooth Sensitivity","Teeth Whitening"],"enrollment":72,"completionDate":"2026-03-02"},{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":["Heart Failure"],"enrollment":46,"completionDate":"2025-05-22"},{"nctId":"NCT07429201","phase":"NA","title":"Comparing an Electrolyte-Carbohydrate Beverage to Water During Ramadan","status":"COMPLETED","sponsor":"PepsiCo Global R&D","startDate":"2026-02-11","conditions":["Hydration Status","Dietary Intake"],"enrollment":60,"completionDate":"2026-03-06"},{"nctId":"NCT06256328","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2024-01-10","conditions":["Gastric Cancer"],"enrollment":226,"completionDate":"2027-07-31"},{"nctId":"NCT07467213","phase":"PHASE4","title":"Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2026-04-01","conditions":["Acute Myocardial Infarction (AMI)","Gastrointestinal Bleeding"],"enrollment":5000,"completionDate":"2030-12-31"},{"nctId":"NCT05558267","phase":"NA","title":"Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2027-01-15","conditions":["End Stage Kidney Disease"],"enrollment":20,"completionDate":"2027-06-15"},{"nctId":"NCT02627196","phase":"NA","title":"Baroreflex Activation Therapy for Heart Failure","status":"COMPLETED","sponsor":"CVRx, Inc.","startDate":"2016-04-19","conditions":["Heart Failure"],"enrollment":1090,"completionDate":"2023-10"},{"nctId":"NCT07460882","phase":"NA","title":"The Impact of Low Sodium Salt Substitute Use on Serum Potassium Levels Among Patients With Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-04-01","conditions":["Hypertension"],"enrollment":607,"completionDate":"2027-09-30"},{"nctId":"NCT06953986","phase":"NA","title":"A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks","status":"RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2025-12-20","conditions":["GERD"],"enrollment":414,"completionDate":"2027-12-12"},{"nctId":"NCT06750653","phase":"PHASE4","title":"Skin Barrier Function and Inflammation in Aging: The BIA Study","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-02-06","conditions":["Inflammation","Skin Inflammation","Aging"],"enrollment":32,"completionDate":"2026-04-15"},{"nctId":"NCT04102371","phase":"PHASE3","title":"Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2020-08-25","conditions":["Shock","Septic"],"enrollment":9041,"completionDate":"2026-01-31"},{"nctId":"NCT07451561","phase":"NA","title":"Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03","conditions":["Acute Aluminum Phosphide Poisoned Cases"],"enrollment":74,"completionDate":"2027-03"},{"nctId":"NCT07451171","phase":"PHASE2","title":"Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":["Small Intestine Bacterial Overgrowth"],"enrollment":60,"completionDate":"2026-06"},{"nctId":"NCT07284069","phase":"EARLY_PHASE1","title":"Senicapoc and Perampanel for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2026-03-01","conditions":["Glioblastoma"],"enrollment":36,"completionDate":"2028-11-01"},{"nctId":"NCT06835829","phase":"NA","title":"Comparing Advanced Hemostasis and Ultrasound-Guided Puncture to Conventional Approaches in Distal Radial Access","status":"RECRUITING","sponsor":"Associazione per lo Studio delle Malattie Cardiovascolari Cardiva ONLUS","startDate":"2025-12-31","conditions":["Coronary Catheterization"],"enrollment":480,"completionDate":"2026-09-30"},{"nctId":"NCT04101188","phase":"NA","title":"Mechanisms Underlying the Protective Vascular Effects of Dietary Potassium in Humans","status":"RECRUITING","sponsor":"University of Delaware","startDate":"2020-01-16","conditions":["Cardiovascular Risk Factor"],"enrollment":90,"completionDate":"2026-07-31"},{"nctId":"NCT07196865","phase":"NA","title":"Comparison of the Clinical Effects of Open, Closed, and Semi-close Hemorrhoidectomy.","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Putian University","startDate":"2026-04-01","conditions":["Hemorrhoids"],"enrollment":378,"completionDate":"2026-12-30"},{"nctId":"NCT07447583","phase":"NA","title":"Traditional vs. Minimally Invasive Decay Treatments in Primary Molars: An 18-month Split-mouth Randomized Study","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2024-08-01","conditions":["Dental Caries"],"enrollment":60,"completionDate":"2026-02-09"},{"nctId":"NCT06076304","phase":"PHASE4","title":"Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis","status":"RECRUITING","sponsor":"Daniel Merenstein","startDate":"2023-11-21","conditions":["Sinus Infection","Acute Sinusitis"],"enrollment":3720,"completionDate":"2028-12"},{"nctId":"NCT07442448","phase":"PHASE4","title":"Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure","status":"ENROLLING_BY_INVITATION","sponsor":"Cathay General Hospital","startDate":"2026-04","conditions":["Heart Failure and Preserved Ejection Fraction","Heart Failure","Heart Failure and Mildly Reduced Ejection Fraction"],"enrollment":40,"completionDate":"2029-12"},{"nctId":"NCT07444203","phase":"","title":"Transformative Research in Diabetic Nephropathy 2.0","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-11-12","conditions":["Diabetic Nephropathies","Kidney Diseases","Renal Insufficiency, Chronic","Diabetes Mellitus, Type 2"],"enrollment":200,"completionDate":"2028-11-12"},{"nctId":"NCT06494072","phase":"PHASE4","title":"Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2024-08-22","conditions":["Community Acquired Pneumonia in Children"],"enrollment":236,"completionDate":"2028-05"},{"nctId":"NCT07437430","phase":"NA","title":"Evaluation of Food Additive Contributions to Obesity: Pilot Study 1","status":"RECRUITING","sponsor":"McMaster University","startDate":"2026-02-10","conditions":["Obesity (Disorder)"],"enrollment":20,"completionDate":"2026-06"},{"nctId":"NCT07435714","phase":"NA","title":"Facilitating Surgical Choice in Patient With Chronic Hypertrophic Rhinitis Using a Patient Decision Aid","status":"NOT_YET_RECRUITING","sponsor":"Taipei Medical University Shuang Ho Hospital","startDate":"2026-02-01","conditions":["Allergic Rhinitis"],"enrollment":158,"completionDate":"2027-07-31"},{"nctId":"NCT07437768","phase":"NA","title":"Vonoprazan Test for PPI Refractory GERD","status":"ENROLLING_BY_INVITATION","sponsor":"Fu Jen Catholic University Hospital","startDate":"2025-12-24","conditions":["Refractory GERD","NERD","PCAB"],"enrollment":100,"completionDate":"2026-10-28"},{"nctId":"NCT06393049","phase":"NA","title":"Microdialysis and Jugular Bulb Glucose Profiles During Hyperglycaemic Clamping in Patients With Severe Acute Brain Injury","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2024-05-08","conditions":["Acute Brain Injury"],"enrollment":14,"completionDate":"2025-12-31"},{"nctId":"NCT07029503","phase":"PHASE2","title":"Swedish Cardiac And Renal Failure Study-1","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2026-02","conditions":["HFrEF - Heart Failure With Reduced Ejection Fraction","Chronic Kidney Disease"],"enrollment":40,"completionDate":"2027-10"},{"nctId":"NCT06624956","phase":"PHASE4","title":"Prevention and Treatment of Common Hyperglycemia in Surgery Pilot","status":"COMPLETED","sponsor":"University of Washington","startDate":"2024-09-04","conditions":["Surgery","Non Diabetic Hyperglycemia"],"enrollment":106,"completionDate":"2026-01-01"},{"nctId":"NCT07221448","phase":"NA","title":"Sodium vs Potassium Education to Improve Vascular Health","status":"RECRUITING","sponsor":"Florida State University","startDate":"2026-03-02","conditions":["Healthy"],"enrollment":32,"completionDate":"2027-09-30"},{"nctId":"NCT07422974","phase":"","title":"Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer","status":"RECRUITING","sponsor":"Osijek University Hospital","startDate":"2026-01-09","conditions":["Colorectal Carcinoma (CRC)","Complications","Neoadjuvant Therapy","Endothelial Dysfunction"],"enrollment":68,"completionDate":"2027-05-01"},{"nctId":"NCT07419763","phase":"NA","title":"Intra Oral Appliance (IOA) Model Evaluating the Efficacy of Sensitive Toothpaste","status":"COMPLETED","sponsor":"Church & Dwight Company, Inc.","startDate":"2025-04-15","conditions":["Dental Caries"],"enrollment":30,"completionDate":"2025-06-10"},{"nctId":"NCT05425030","phase":"NA","title":"A Community Health Worker-Led LSSS Intervention in Bangladesh","status":"COMPLETED","sponsor":"Stanford University","startDate":"2023-01-26","conditions":["Blood Pressure","Hypertension"],"enrollment":618,"completionDate":"2024-12-01"},{"nctId":"NCT06811363","phase":"","title":"Contribution of Bone to Urine Citrate","status":"ENROLLING_BY_INVITATION","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02-28","conditions":["Osteoporosis"],"enrollment":25,"completionDate":"2027-03"},{"nctId":"NCT07293910","phase":"PHASE2","title":"Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Tanta University","startDate":"2026-02-15","conditions":["HELICOBACTER PYLORI INFECTIONS","Helicobacter Infection","Helicobacter Pylori Gastrointestinal Tract Infection","Helicobacter Pylori Infected Patients"],"enrollment":66,"completionDate":"2026-12-20"},{"nctId":"NCT04651088","phase":"EARLY_PHASE1","title":"Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-07-01","conditions":["Kidney Stone"],"enrollment":15,"completionDate":"2027-07"},{"nctId":"NCT06094920","phase":"PHASE4","title":"Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2024-07-29","conditions":["Diabetes Mellitus Type 2 With Proteinuria","Diabetes Mellitus, Type 2","Diabetes Mellitus","Diabetes","Diabetes Complications","Albuminuria","Chronic Kidney Diseases","Chronic Kidney Disease Due to Type 2 Diabetes Mellitus","Chronic Kidney Disease stage3","Chronic Kidney Disease stage4","CKD","CKD Stage 3","CKD Stage 4"],"enrollment":12,"completionDate":"2025-09-24"},{"nctId":"NCT07059065","phase":"NA","title":"FIBERGRAFT Aeridyan Posterolateral Fusion Study","status":"RECRUITING","sponsor":"DePuy Synthes Products, Inc.","startDate":"2025-08-15","conditions":["Degenerative Spine Disease"],"enrollment":316,"completionDate":"2028-12-29"},{"nctId":"NCT04966507","phase":"PHASE2","title":"Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-02-17","conditions":["Gonorrhea"],"enrollment":89,"completionDate":"2025-12-12"},{"nctId":"NCT07408076","phase":"PHASE1,PHASE2","title":"Sodium Bicarbonate as an Alternative to Potassium Citrate for Kidney Stones","status":"NOT_YET_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2026-02-01","conditions":["Kidney Stones, Urolithiasis, Hypocitraturia","Nephrolithiasis"],"enrollment":30,"completionDate":"2028-02-01"},{"nctId":"NCT06366230","phase":"PHASE1,PHASE2","title":"Adding Urea to the Final Dialysis Fluid","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-09-16","conditions":["Dysequilibrium Syndrome","ESRD","Hyperkalemia","Metabolic Acidosis"],"enrollment":20,"completionDate":"2028-06-30"},{"nctId":"NCT06731270","phase":"PHASE2","title":"Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-04-09","conditions":["Advanced Lung Non-Small Cell Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8"],"enrollment":20,"completionDate":"2028-01-01"},{"nctId":"NCT07405684","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp First-line Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":["HELICOBACTER PYLORI INFECTIONS"],"enrollment":544,"completionDate":"2028-12-31"},{"nctId":"NCT03253172","phase":"NA","title":"Potassium Supplementation in CKD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2017-07-01","conditions":["Renal Insufficiency, Chronic","Potassium Depletion","Hypertension","Hyperkalemia"],"enrollment":532,"completionDate":"2026-10-01"},{"nctId":"NCT07405697","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp Rescue Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":["Helicobacter Pylori Infection"],"enrollment":290,"completionDate":"2028-12-31"},{"nctId":"NCT06381934","phase":"NA","title":"Validation of New Diagnostic Indices to Simplify Hyponatremia Therapy Assessment in Patients on Thiazide Diuretics","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2024-05-06","conditions":["Thiazide Associated Hyponatremia"],"enrollment":136,"completionDate":"2027-04"},{"nctId":"NCT07403305","phase":"NA","title":"The Effect of Water Physical Exercise Program in Thermal Water and Hydropinotherapy on Cardiovascular Health","status":"NOT_YET_RECRUITING","sponsor":"Instituto Politécnico de Bragança","startDate":"2026-01-19","conditions":["Cardiovascular (CV) Risk"],"enrollment":80,"completionDate":"2026-10-31"},{"nctId":"NCT07023315","phase":"PHASE3","title":"A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-08-14","conditions":["Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma"],"enrollment":760,"completionDate":"2031-07"},{"nctId":"NCT04856488","phase":"PHASE3","title":"Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter","status":"RECRUITING","sponsor":"Jan Calissendorff","startDate":"2021-11-18","conditions":["Hyperthyroidism"],"enrollment":182,"completionDate":"2028-12"},{"nctId":"NCT07400016","phase":"NA","title":"Efficacy of Superoxide Dismutase Spray in Preventing Radiation Dermatitis in Patients With Head and Neck Cancer .","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-02-10","conditions":["Radiation Dermatitis"],"enrollment":140,"completionDate":"2027-01-31"},{"nctId":"NCT07215767","phase":"PHASE3","title":"Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice","status":"RECRUITING","sponsor":"HALEON","startDate":"2025-09-16","conditions":["Dentin Hypersensitivity"],"enrollment":850,"completionDate":"2026-08"},{"nctId":"NCT06819111","phase":"PHASE1","title":"Role of Medication in Making Urine Less Acidic as Part of Kidney Stone Prevention","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-07-01","conditions":["Kidney Calculi"],"enrollment":20,"completionDate":"2027-10-31"},{"nctId":"NCT07389837","phase":"NA","title":"Maple Syrup Carbohydrate Dose-Response on 20-km Cycling Time-Trial Performance","status":"NOT_YET_RECRUITING","sponsor":"Université de Montréal","startDate":"2026-02-01","conditions":["Exercise","Endurance Cycling Performance","Carbohydrate Intolerance","Sport Nutrition"],"enrollment":32,"completionDate":"2027-06-01"},{"nctId":"NCT06920914","phase":"NA","title":"Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD","status":"NOT_YET_RECRUITING","sponsor":"University of Alberta","startDate":"2026-07-01","conditions":["Chronic Kidney Disease"],"enrollment":48,"completionDate":"2028-06-01"},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":["Recurrent Medulloblastoma","Recurrent Ependymoma"],"enrollment":62,"completionDate":"2027-09-30"},{"nctId":"NCT05844501","phase":"PHASE4","title":"Ondansetron for the Management of Atrial Fibrillation","status":"RECRUITING","sponsor":"Indiana University","startDate":"2025-04-22","conditions":["Atrial Fibrillation"],"enrollment":80,"completionDate":"2027-12-31"},{"nctId":"NCT07189091","phase":"PHASE4","title":"CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2025-10-07","conditions":["Critical Care, Intensive Care","Fluid Accumulation","Fluid and Electrolyte Imbalance","Critical Illness","Fluid Balance Outcomes"],"enrollment":640,"completionDate":"2028-07-30"},{"nctId":"NCT05100654","phase":"EARLY_PHASE1","title":"Collaborative Urological Prosthetics Investigation Directive Research Group","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2022-04-22","conditions":["Erectile Dysfunction","Penile Prosthesis Infection"],"enrollment":800,"completionDate":"2028-01-01"},{"nctId":"NCT05867121","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-10-02","conditions":["Non-small Cell Lung Cancer","Gastric Cancer","Pancreatic Ductal Adenocarcinoma"],"enrollment":102,"completionDate":"2026-06-30"},{"nctId":"NCT06786260","phase":"NA","title":"Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney Disease","status":"NOT_YET_RECRUITING","sponsor":"Loma Linda University","startDate":"2026-05","conditions":["Autosomal Dominant Polycystic Kidney Disease (ADPKD)"],"enrollment":30,"completionDate":"2027-04"},{"nctId":"NCT05828823","phase":"NA","title":"Incremental Hemodialysis: The TwoPlus Trial","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-02-26","conditions":["End-Stage Kidney Disease"],"enrollment":350,"completionDate":"2028-03"},{"nctId":"NCT04591210","phase":"PHASE3","title":"The COVID-RASi Trial (COVID-19)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-01-27","conditions":["COVID-19","Cardiovascular Diseases"],"enrollment":372,"completionDate":"2024-12-30"},{"nctId":"NCT07368946","phase":"NA","title":"Phosphate Assessment in Chronic Kidney Disease Patients Study","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-05-09","conditions":["Chronic Kidney Disease (Stage 3-4)","Chronic Kidney Disease Mineral and Bone Disorder"],"enrollment":60,"completionDate":"2026-12-31"},{"nctId":"NCT07370194","phase":"","title":"Observational Study on the Prevalence and Risk Factors of Patients With Hyperkalaemia in Brazil","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-28","conditions":["Hyperkalemia"],"enrollment":6215,"completionDate":"2026-09-30"},{"nctId":"NCT06229288","phase":"PHASE3","title":"Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-04-25","conditions":["Community-acquired Pneumonia"],"enrollment":326,"completionDate":"2027-05-25"},{"nctId":"NCT07358065","phase":"NA","title":"Clinical Application of Dynamic Multimodal Analgesia Regimen After Perianal Abscess Surgery","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Putian University","startDate":"2026-01-01","conditions":["Clinical Application of Dynamic Multimodal Analgesia Regimen After Perianal Abscess Surgery"],"enrollment":135,"completionDate":"2026-12-31"},{"nctId":"NCT06510010","phase":"PHASE2","title":"Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-12-31","conditions":["Chemotherapy Effect"],"enrollment":198,"completionDate":"2027-07-31"},{"nctId":"NCT06114498","phase":"","title":"Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2023-09-01","conditions":["Heart Failure With Preserved Ejection Fraction","Obesity, Mild","Decompensated Heart Failure"],"enrollment":240,"completionDate":"2026-07-31"},{"nctId":"NCT07167862","phase":"PHASE4","title":"Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound","status":"NOT_YET_RECRUITING","sponsor":"University of California, Irvine","startDate":"2026-06-15","conditions":["Preeclampsia","Preeclampsia Postpartum","Preeclampsia Severe or Mild"],"enrollment":96,"completionDate":"2028-06-15"},{"nctId":"NCT06761846","phase":"PHASE2","title":"Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-01-17","conditions":["Gastric Adenocarcinoma","Esophagogastric Junction Adenocarcinoma"],"enrollment":70,"completionDate":"2028-12-31"},{"nctId":"NCT06808971","phase":"PHASE2","title":"Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-02-28","conditions":["Gastric Adenocarcinoma","Gastro-esophageal Junction Adenocarcinoma"],"enrollment":61,"completionDate":"2027-12-31"},{"nctId":"NCT07355816","phase":"NA","title":"Effect of Different Root Canal Disinfection Procedures on Postoperative Pain","status":"COMPLETED","sponsor":"Cumhuriyet University","startDate":"2023-06-13","conditions":["Pain, Postoperative"],"enrollment":80,"completionDate":"2024-11-11"},{"nctId":"NCT05389995","phase":"NA","title":"Potassium Citrate and Crystal Light Lemonade","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2022-08-01","conditions":["Kidney Stone"],"enrollment":10,"completionDate":"2027-01-31"},{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":["Heart Failure With Reduced Ejection Fraction","Coronary Artery Disease"],"enrollment":654,"completionDate":"2028-01-30"},{"nctId":"NCT06426836","phase":"NA","title":"Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2016-08-19","conditions":["Pharmacokinetics","Amoxicillin-clavulanate","Piperacillin-tazobactam","Meropenem","Cefazolin","Teicoplanin","Vancomycin","Ciprofloxacin","Amikacin"],"enrollment":300,"completionDate":"2026-07-01"},{"nctId":"NCT05090865","phase":"NA","title":"Dietary Potassium Liberalization in Pre-Dialysis Patients","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2024-01-15","conditions":["Chronic Kidney Disease","Hyperkalemia"],"enrollment":30,"completionDate":"2026-05-31"},{"nctId":"NCT07244029","phase":"NA","title":"Aescin-Based Herbal Extract (Reparil) for Postoperative Sequelae After Mandibular Third Molar Surgery","status":"RECRUITING","sponsor":"Oman Medical Speciality Board","startDate":"2026-01-01","conditions":["Postoperative Pain","Facial Swelling","Trismus"],"enrollment":100,"completionDate":"2026-09-30"},{"nctId":"NCT07297732","phase":"NA","title":"A Study to Investigate the Tooth Whitening and Dentin Hypersensitivity Effectiveness of Two Experimental Toothpastes","status":"RECRUITING","sponsor":"HALEON","startDate":"2025-12-15","conditions":["Dentin Hypersensitivity"],"enrollment":105,"completionDate":"2026-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"For Solution","formulations":[{"form":"FOR SOLUTION","route":"ORAL","productName":""}]},"_patentsChecked":true,"crossReferences":{"UNII":"660YQ98I10","RXCUI":"312529,628953","SPL_ID":"3f74c669-3182-952f-e063-6294a90aad92","chemblId":"CHEMBL1141"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"2025-","companyName":"Torrent","relationship":"Original Developer"},{"period":"present","companyName":"Nesher Pharms","relationship":"Current Owner"}],"publicationCount":176803,"therapeuticAreas":["Metabolic"],"applicationNumber":"ANDA215891","biosimilarFilings":[],"originalDeveloper":"Torrent","recentPublications":[{"date":"2026 Mar 30","pmid":"41913095","title":"Beyond silver: innovative use of gold nanoparticles for anthracnose management and plant immunity enhancement in chilli.","journal":"Pest management science"},{"date":"2026 Mar 31","pmid":"41912740","title":"A potassium titanate whisker-assisted method for genetic transformation of Phanerochaete chrysosporium using a Cas9-sGFP expression vector.","journal":"World journal of microbiology & biotechnology"},{"date":"2026 Mar 31","pmid":"41911485","title":"The use of potassium-competitive acid blockers in the management of foregut disease.","journal":"Current opinion in gastroenterology"},{"date":"2026 Mar 30","pmid":"41910839","title":"MitoQ Triggers Mitochondrial Collapse and Apoptotic Death in Glioblastoma Associated with KATP Channel Expression Changes.","journal":"Neurochemical research"},{"date":"2026 Mar 1","pmid":"41910484","title":"Fractional Excretion of Potassium Predicts Remission in Adult Nephrotic Syndrome.","journal":"Kidney360"}],"companionDiagnostics":[],"genericManufacturers":56,"_genericFilersChecked":true,"genericManufacturerList":["Abraxis Pharm","Actavis Labs Fl Inc","Adare Pharms Inc","Ajenat Pharms","Amneal","Amneal Pharms","Anda Repository","Apotex","Ascent Pharms Inc","Aurobindo Pharma","Aurobindo Pharma Ltd","B Braun","Baxter Hlthcare","Breckenridge","Chartwell Molecular","Chartwell Rx","Copley Pharm","Epic Pharma Llc","Fresenius Kabi Usa","Future Pak","Gd Searle Llc","Glenmark Pharms Ltd","Granules","Guangzhou Novaken","Hospira","Intl Medication","Luitpold","Lupin Ltd","Macleods Pharms Ltd","Miles","Nesher Pharms","Nexus","Novel Labs Inc","Novitium Pharma","Padagis Us","Ph Health","Pharm Assoc","Pharma Serve Ny","Pharmobedient","Prinston Inc","Quagen","Rising","Rubicon Research","Savage Labs","Sciegen Pharms","Sigmapharm Labs Llc","Strides Pharma","Taro","Teva","Tris Pharma Inc","Twi Pharms","Upsher Smith Labs","Watson Labs","Wes Pharma Inc","Yichang Humanwell","Zydus Pharms"],"status":"active","companyName":"Nesher Pharms","companyId":"nesher-pharms","modality":"Small molecule","firstApprovalDate":"2025","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1984-02-28T00:00:00.000Z","mah":"BAXTER HLTHCARE","brand_name_local":null,"application_number":"NDA018494"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-03-24T00:00:00.000Z","mah":"RUBICON RESEARCH","brand_name_local":null,"application_number":"ANDA214108"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-06-29T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"ANDA215370"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-05-08T00:00:00.000Z","mah":"VERASTEM INC","brand_name_local":null,"application_number":"NDA219616"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-10-27T00:00:00.000Z","mah":"TWI PHARMS","brand_name_local":null,"application_number":"ANDA218979"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"TORRENT","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":15,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:44:26.735870+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}